| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT06699849 Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle… |
Trial sites expanded: 19 -> 26 locations |
| 2026-08-12 | NCT05485961 Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects… |
Trial sites expanded: 548 -> 557 locations |
| 2026-08-06 | NCT07224360 Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) |
Trial sites expanded: 5 -> 16 locations |
| 2026-07-29 | NCT06003387 Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With… |
Trial sites expanded: 27 -> 30 locations |
| 2026-07-24 | NCT06806657 Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to… |
Trial completed |
| 2026-07-24 | NCT06399289 Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese… |
Trial completed |
| 2026-07-24 | NCT06399289 Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese… |
date change Primary completion moved earlier: 2026-12-01 -> 2026-07-07 |
| 2026-07-24 | NCT06399289 Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese… |
date change Completion moved earlier: 2026-12-01 -> 2026-07-07 |
| 2026-07-23 | NCT07648264 Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to… |
Trial sites expanded: 0 -> 60 locations |
| 2026-07-21 | NCT07080905 Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to <… |
Trial sites expanded: 2 -> 12 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT03684018 | Two Dose Levels of Privigen in Pediatric CIDP | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Recruiting |
| NCT07326592 | Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung… | Alpha1 Antitrypsin Deficiency | Not Yet Recruiting |
| Phase 3 | |||
| NCT06617897 | Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei… | Acquired Fibrinogen Deficiency | Recruiting |
| NCT07094087 | Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult… | Complex Cardiovascular Surgery With Cardiopulmonary Bypass | Recruiting |
| NCT07080905 | Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to <… | Hemophilia B | Recruiting |
| NCT06003387 | Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With… | Hemophilia B | Recruiting |
| NCT06738485 | Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With… | Congenital Hemophilia A | Active, Not Recruiting |
| NCT07648264 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to… | Secondary Immune Deficiency | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT05485961 | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects… | End Stage Kidney Disease | Recruiting |
| Phase 2 | |||
| NCT07048262 | Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With… | Non-cystic Fibrosis Bronchiectasis | Recruiting |
| NCT07332091 | Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator… | Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | Recruiting |
| NCT07224360 | Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) | Sickle Cell Disease | Recruiting |
| NCT06699849 | Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle… | Sickle Cell Disease Vaso-occlusive Crisis | Recruiting |
| Phase 1 | |||
| NCT07619820 | A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End… | End Stage Kidney Disease (ESKD) | Recruiting |
| Not specified | |||
| NCT04672733 | Hizentra® in Inflammatory Neuropathies - pHeNIx Study | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting |
| NCT06008938 | An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX®… | Hemophilia B | Recruiting |
| NCT07001280 | A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients… | Hereditary Angioedemas | Recruiting |
| NCT05086575 | Observatory of Patients With Haemophilia B Treated by IdElvion® | Haemophilia B | Active, Not Recruiting |
| NCT05962398 | Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With… | Hemophilia B | Enrolling by Invitation |